Mianserin Viatris

Mianserin, the active ingredient in Mianserin Viatris, is a tetracyclic antidepressant presented as a tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients. GNH USA supplies Mianserin Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mianserin is a tetracyclic antidepressant that acts on mood‑regulating pathways.

Major depressive disorder: reduces depressive symptoms in adults Depressive symptoms in elderly patients: helps improve mood and sleep quality Depressive episodes with prominent anxiety: may alleviate associated anxiety features

Mianserin may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Drowsiness or sedation - Dry mouth - Increased appetite and weight gain - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Cardiac arrhythmias (e.g., QT prolongation) - Severe hypotension or syncope - Hepatotoxicity - Seizures - Extrapyramidal symptoms

When prescribing Mianserin, clinicians should consider several safety measures.

Dose titration: start low and increase gradually to minimize sedation Cardiovascular monitoring: assess ECG for QT interval changes Hematologic surveillance: monitor white blood cell counts periodically Liver function: evaluate hepatic enzymes before and during therapy Avoid abrupt discontinuation: taper dose to reduce withdrawal effects Store at ambient temperature: keep in original container, protect from moisture and direct sunlight

Mianserin can affect the activity of other medicines; awareness of key interactions helps avoid adverse outcomes.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis or serotonin syndrome - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression - Drugs that prolong QT interval: increased risk of cardiac arrhythmias

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., metoprolol, codeine): possible altered plasma levels - Anticholinergic agents: enhanced dry mouth and constipation - Antihypertensives: potential additive hypotensive effect